Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theralase Technologies Inc.
TLTFF
Primary Symbol:
V.TLT
Healthcare
Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called...
Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.
see more
Get updates on Theralase Technologies Inc. delivered in your email.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
I consent to receiving electronic messages from Theralase Technologies Inc. and Stockhouse.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (TSXV:TLT)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(2432)
•••
Eoganacht
X
View Profile
View Bullboard History
Comment by
Eoganacht
on Nov 21, 2024 5:06pm
RE:Next NR
We should get the 3Q2024 financials and MD&A by the end of next week.
(252)
•••
rhodiumd
X
View Profile
View Bullboard History
Post by
rhodiumd
on Nov 21, 2024 4:35pm
Next NR
Next NR could very well be BTD approval... Tic toc...
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(1192)
•••
CancerSlayer
X
View Profile
View Bullboard History
Comment by
CancerSlayer
on Nov 21, 2024 3:44pm
RE:RE:FDA focused?
An FDA that lacks a revolving door would be a good start.
(1192)
•••
CancerSlayer
X
View Profile
View Bullboard History
Comment by
CancerSlayer
on Nov 21, 2024 3:40pm
RE:New BCG-Unresponsive NMIBC Treatment Review Study
Thanks Eoganacht....All factors considered (our current 12 month CR at ~27% & 12 month ORR at 71% across 68 patients, excellent safety profile & likely high cost-effectiveness...considering we
...more
(11)
•••
bmk211
X
View Profile
View Bullboard History
Comment by
bmk211
on Nov 21, 2024 3:12pm
RE:FDA focused?
I was worried about the same thing. But truthfully as hard as it may seem to belive. Things usually do get worse before they get better when corruption is involved. But in the
...more
(38)
•••
Gman620
X
View Profile
View Bullboard History
Post by
Gman620
on Nov 21, 2024 1:53pm
FDA focused?
I hope that the people at the FDA are not distracted by shredding documents and doing CYA activities instead of doing their job and pushing through this BTD. Any indication that things are on hold
...more
(567)
•••
Galaxym31
X
View Profile
View Bullboard History
Comment by
Galaxym31
on Nov 21, 2024 1:21pm
RE:RE:Went back 17 pages on Dumbles post pages
Sensitive boy .
(1067)
•••
StevenBirch
X
View Profile
View Bullboard History
Comment by
StevenBirch
on Nov 21, 2024 12:10pm
RE:New BCG-Unresponsive NMIBC Treatment Review Study
Sounds to me like TLT, facing long odds and great difficulty, is...{^youtubevideo|(width)425|(height)264|(rel)False|(url)https://www.youtube.com/watch?v=qrvP02Oit04|(fs)True|(loop)False|(autoplay
...more
(19)
•••
digitalstone
X
View Profile
View Bullboard History
Comment by
digitalstone
on Nov 21, 2024 12:00pm
RE:New BCG-Unresponsive NMIBC Treatment Review Study
Nice to see Dr.Ashish Kamat involved in the above article!
(2432)
•••
Eoganacht
X
View Profile
View Bullboard History
Post by
Eoganacht
on Nov 21, 2024 11:28am
New BCG-Unresponsive NMIBC Treatment Review Study
European Urology Oncology Available online 15 November 2024 David D’Andrea, Hugh Mostafid, Paolo Gontero, Shahrokh Shariat, Ashish Kamat, Alexandra Masson-Lecomte, Maximilian Burger, Morgan
...more
(664)
•••
DeathXray33
X
View Profile
View Bullboard History
Comment by
DeathXray33
on Nov 21, 2024 7:23am
RE:RE:Went back 17 pages on Dumbles post pages
I've been stalked at grocery stores and gas stations for 7 years by a political mob. Even my cellphone and financial content was given out illegally. Someone from law enforcement has been doing it
...more
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Nov 21, 2024 6:55am
Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed
A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results.
read article.
(441)
•••
BlueFranky
X
View Profile
View Bullboard History
Comment by
BlueFranky
on Nov 20, 2024 9:22pm
RE:RE:RE:RE:RE:RE:RE:RE:2025 Outlook
It's totally surreal. To think that we're sitting next to a soon to be preeminent FDA endosed molecule, potentially capable of treating innumerable types of cancer...with grandkids one
...more
(1192)
•••
CancerSlayer
X
View Profile
View Bullboard History
Comment by
CancerSlayer
on Nov 20, 2024 8:58pm
RE:RE:RE:RE:RE:RE:RE:RE:2025 Outlook
Correction... 7) Achieving efficacy & durability, but at the expense of one or a combination of the first four (not three) I lost count...
(1192)
•••
CancerSlayer
X
View Profile
View Bullboard History
Comment by
CancerSlayer
on Nov 20, 2024 8:43pm
RE:RE:RE:RE:RE:RE:RE:2025 Outlook
Certainly....if we were to put a lens on just clinical development stage/progress, being a company with a nearly completed Ph II (& no requirements for a Ph III) & assuming we obtain a BTD
...more
(421)
•••
Infinity
X
View Profile
View Bullboard History
Comment by
Infinity
on Nov 20, 2024 7:02pm
RE:RE:RE:RE:RE:RE:RE:RE:2025 Outlook
The outlook for 2025 is not good it is not better it is the BEST. My gut feeling, we will get BTD in 2024. We may even AA. After that, we need a Big Pharma to carry on to get FDA
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden